Drug intelligence / Profile preview

Pregnafol DHA

Development stage: Unknown
Lead developer: Mercury Laboratories
Modality: Small Molecules
Administration: Oral

Overview

Pregnafol DHA (also known as Pregnafol D) is a prenatal nutritional supplement developed and marketed by Mercury Laboratories, an Indian pharmaceutical company. The product is a combination of docosahexaenoic acid (DHA), an essential omega-3 fatty acid, and folic acid, often supplemented with mecobalamin (methylcobalamin). It is specifically formulated to support maternal health and fetal development during pregnancy. DHA is critical for the development of the fetal brain and retina, while folic acid is essential for DNA synthesis and the prevention of neural tube defects. The supplement is typically administered orally in capsule form and is approved for use in the Indian market.

Brand names: Pregnafol DHAPregnafol-DHAPregnafol D
Other names: Pregnafol + docosahexaenoic acid

Beyond the preview

Go deeper on Pregnafol DHA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pregnafol DHA.

Explore the full profile